Organisation paid for research Program year 2025 Source: CMS Open Payments

Chesapeake Urology

Neither a doctor nor a teaching hospital

Research payments

$591,408

52 payments

Through program year 2025, Chesapeake Urology is reported as receiving $591,408 in research payments, across 52 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $51,337 3
2024 Research $91,650 4
2023 Research $106,743 7
2022 Research $98,241 6
2021 Research $228,285 19
2020 Research $3,003 5
2019 Research $12,150 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $202,907 4 payments
  2. Eli Lilly and Company $196,433 7 payments
  3. GlaxoSmithKline, LLC. $91,497 26 payments
  4. Myriad Genetic Laboratories, Inc. $87,975 4 payments
  5. Ipsen Innovation $9,654 4 payments
  6. Allergan Inc. $1,402 2 payments
  7. Pfizer Inc. $1,094 2 payments
  8. Medtronic, Inc. $446 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2, single arm study of CG0070 combined with pembrolizumab in subjects with Non-Muscle Invasive Bladder Cancer NMIBC unresponsive to Bacillus Calmette-Guerin BCG $162,400 2 payments
  2. Cyclone 3: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer $93,954 2 payments
  3. A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, DO $90,435 25 payments
  4. Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer $87,975 4 payments
  5. Cyclone 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer $57,820 3 payments
  6. Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) $24,886 1 payment
  7. A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor $21,041 1 payment
  8. A Phase 3, Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent NHA $19,466 1 payment
  9. A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis $9,654 4 payments
  10. A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Single Treatment, 2-Stage, Dose Finding Study Evaluating the Efficacy and Safety of Botox Intravesical Installation in Participants With Overactive Bladder and Urinary Incontinence. $1,402 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record